With the significant growth of cannabinoid IP in the past few years, eyes are now on the emerging psychedelics market as the next frontier for IP protection. Gretchen Temeles of Hiller and Timothy Schlidt of Palo Santo Ventures discuss the issues.
Mexico’s updated IP laws seek to avoid the patentability of plants obtained by essentially biological processes—creating issues for plant rights owners, explains Corina Silva of Uhthoff, Gómez Vega & Uhthoff.
Recent changes to patent law in China sees registration, review and litigation fall in line with established international IP systems, say Venable partners Keith Haddaway and Christopher Loh.
The latest episode in the long-running dispute between the NHS and French pharmaceutical company Servier has been marked by a UK Supreme Court judgment of July 2, 2021 on Servier’s application to strike out the NHS’s unlawful means tort claim.
A Japanese think tank is recommending an overhaul of Japan’s drug pricing system. Takanori Abe of Abe and Partners reports.
In the final article of a four-part series, Sophie Topham of Marks & Clerk discusses the supplementary protection certificate manufacturing waiver.
In the third article of a four-part series on experimental use exemptions from infringement in the UK, Sophie Topham of Marks & Clerk considers the expansion of the original exemption.
Is the ‘essentially derived varieties’ concept protecting plant varieties or chilling innovation, ask Joel Smith and Burkhart Goebel of Hogan Lovells.
In the second of a four-part series, Sophie Topham of Marks & Clerk explains the rules around the exemption for studies, tests, and trials required for generic and biosimilar medicines.
In the first of a four-part series, Sophie Topham of Marks & Clerk explores how experimental use provides life sciences products with essential relief from patent infringement